-
Trial Shows Some ALS Drug Benefit for Patients
Results from a clinical trial show a drug to treat amyotrophic lateral sclerosis slows the functional decline in ALS patients compared to a placebo.
-
Synthetic Antibodies Neutralize Covid-19 Virus Proteins
A company developing synthetic genetic materials and proteins says independent tests show its artificial antibodies neutralize infection mechanisms in Covid-19 viruses.
-
NIH Nixes Convalescent Plasma Covid-19 Therapy
An expert panel convened by National Institutes of Health says current data do not support recommending convalescent plasma as a treatment for Covid-19 infections.
-
Late-Stage Covid-19 Vaccine Trial Underway in U.S.
Global drug maker AstraZeneca is starting its late-stage Covid-19 vaccine clinical trial in the U.S., with a vow not to cut corners in its processes.
-
Food Allergy Biotech Acquired for $2.6B
Aimmune Therapeutics Inc., a developer of food allergy drugs, was acquired today by global consumer products company Nestlé for $2.6 billion.
-
Covid-19 Vaccines, Therapies – 31 August 2020
The European Commission announced today a contribution of €400 million ($US 477 million) to the COVID-19 Vaccine Global Access, or Covax, consortium.
-
Does Ad Tech Explain The Recession Recovery?
Technology seems to be allowing the factors of production to slosh about at will, without much friction.
-
Taking a Break
We’re taking this week off at Science & Enterprise, to concentrate on a big photography project, and will return on 31 August.
-
Infographic – Biotech Index Cruising in High Range
Looking back to May shows that NBI has largely settled in to the 4,000 to 4,500 range, without volatile swings in either direction.
-
Engineered Mosquitoes Approved for Disease Control
In an apparent end to a long-running dispute, authorities in the Florida Keys approved a field trial of engineered mosquitoes to control tropical diseases.